Citius Pharmaceuticals (CTXR)
(Delayed Data from NSDQ)
$0.60 USD
+0.02 (3.79%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.59 -0.01 (-0.84%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.60 USD
+0.02 (3.79%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.59 -0.01 (-0.84%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Zacks News
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
by Zacks Equity Research
Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.
Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy
by Zacks Equity Research
Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.
Are Options Traders Betting on a Big Move in Citius Pharmaceuticals (CTXR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Citius Pharmaceuticals (CTXR) stock based on the movements in the options market lately.
Citius Pharmaceuticals (CTXR) Jumps: Stock Rises 5.1%
by Zacks Equity Research
Citius Pharmaceuticals (CTXR) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.